AI 聊天
正在加载 BMY 的数据(首次访问,需要几秒钟)。

Bristol-Myers Squibb Company

BMY · NYSE · USD

59.12 -0.46 (-0.77%)

收盘价: Oct 09, 2026, 4:00 PM EDT

59.14 +0.03%

盘后: 7:14 PM

市值
$120.8B
成交量
9.25M
下次财报日期
Oct 29, 2026

Bristol-Myers Squibb Company(BMY)股价、分析与数据

时间间隔:1D
正在加载K线和信号…

内在价值

估值模型属于 Pro 功能。登录或升级后可查看完整分析。

查看方案 →

分析师预测

股票预测 →

目标价

$41.00 – $82.00

中值 $65.50 · 10.79% 上涨空间

12个月目标价 · 24 位分析师

分析师一致意见: 买入

您正在查看免费概览

创建免费账户,探索更多关于此标的的研究资料。

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收$12.97Bn/a+5.74%
每股收益(TTM)$2.04+$0.44+39.73%

下次财报

开盘前。

预估 · 升级 →

查看财报详情 →

指标

买价
59.05
市值
121B
净利润(TTM)
9.28B
0.18
4.5
13.14
8.94
市净率(TTM)
5.41
市销率(TTM)
2.46
财报日期
Oct 29, 2026
卖价
59.42
成交量
9,252,193
20日均量
11,301,554
开盘价
58.88
前收盘价
59.58
日内区间
58.83 - 59.79
52周区间
42.52 - 68.64
分析师
买入
目标价
65.5 (10.79%)
分红
$2.52 (4.23%)
除息日
Oct 2, 2026

关于 Bristol-Myers Squibb Company

查看公司资料 →
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey. Drug Manufacturers - General · Healthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

板块 Healthcare
上市日期 Jun 1, 1972
员工人数 32,500
交易所 NYSE
股票代码 BMY